Latest study shows positive results of CanSinoBIO’s inhaled COVID-19 vaccine as booster

pharmafile | January 11, 2022 | News story | Manufacturing and Production  

CanSino Biologics has announced that a heterologous booster with one dose of the Inhalation Convidecia for adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralising antibodies than those with a homogeneous booster of inactivated vaccine.

The study was randomised, non-blind and parallel-controlled, and had 420 participants randomly assigned to three 140-person groups. The trial showed the safety and immunogenicity of the Inhalation Convidecia as a booster using only one fifth or two fifths dosage of its intramuscular version.

The data on immunogenicity showed that the inhaled heterologous booster elicited a significantly higher level of neutralising antibodies than those with a homogeneous booster of inactivated vaccine. There was no significant difference in immune response between the two inhalation groups, which were 6.7 to 10.7 times higher than that observed in the third group with a homologous booster shot between days 14 and 28 after the booster shot.

As compared to the inactivated booster, significantly increased 2019-nCoV spike protein-specific IFN-y and IL-2 ELISA can be detected seven days after the inhalation booster. This indicates that, compared to the inactivated vaccine homologous booster, the inhaled heterologous booster can significantly reduce Th1-type cellular immune response, while factors such as gender and age have no effect on cellular immune response.

Lina Adams

Related Content

No items found

Latest content